E. Daar

S. J. Clark, G. Shaw, H. Farzadegan, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

gpl20 Important in CD4 Binding and Human Immunodeficiency Virus Type

E. Daar, J. McKeating, L. Xiling, 2022 .

The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.

C. B. Hare, K. Tashima, S. Little, 2012, The Journal of infectious diseases.

Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies

Michael J. Taylor, C. Yiannoutsos, D. Tate, 2011, Journal of NeuroVirology.

Bacterial and Fungal Infections

E. Daar, R. D. Meyer, R. Meyer, 1992 .

Faculty of 1000 evaluation for Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

E. Daar, 2017 .

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

P. Sax, E. Daar, D. Kitch, 2011, The Journal of infectious diseases.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

D. Katzenstein, K. Tashima, P. Sax, 2011, The Journal of infectious diseases.

Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.

M. Lederman, P. Ridker, C. Fichtenbaum, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatitis C virus and death risk in hemodialysis patients.

S. Greenland, K. Kalantar-Zadeh, D. Gjertson, 2007, Journal of the American Society of Nephrology : JASN.

Implementation and Operational Research: The Navigation Program An Intervention to Reengage Lost Patients at 7 HIV Clinics in Los Angeles County, 2012–2014

E. Daar, J. Bailey, A. Wohl, 2016, Journal of acquired immune deficiency syndromes.

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy

R. Haubrich, D. Richman, S. Little, 2015, Scientific Reports.

Perceptions of People Living with HIV and HIV Healthcare Providers on Real-Time Measuring and Monitoring of Antiretroviral Adherence Using Ingestible Sensors: A Qualitative Study

E. Daar, M. Rosen, Honghu Liu, 2020, AIDS research and treatment.

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

E. Daar, K. Workowski, B. Doehle, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Modeling the Impact of Post-Diagnosis Behavior Change on HIV Prevalence in Southern California Men Who Have Sex with Men (MSM)

S. Goodreau, S. Little, E. Daar, 2014, AIDS and Behavior.

Hepatitis C virus and death risk in hemodialysis patients.

S. Greenland, K. Kalantar-Zadeh, D. Gjertson, 2006, Journal of the American Society of Nephrology : JASN.

HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen

R. Haubrich, C. Spina, E. Daar, 2017, HIV clinical trials.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

D. Ward, J. Gallant, M. Johnson, 2016, The lancet. HIV.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

P. Sax, E. Daar, A. Collier, 2014, The Journal of antimicrobial chemotherapy.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events

M. Ritchie, P. Sax, D. Haas, 2018, Pharmacogenetics and genomics.

HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells.

E. Daar, H. Koeffler, H. Taguchi, 2000, Blood.

Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes

Michael J. Taylor, Jeffery R. Alger, P. Thompson, 2010, Journal of NeuroVirology.

Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy

Michael J. Taylor, C. Yiannoutsos, J. Alger, 2015, Journal of acquired immune deficiency syndromes.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials†

H. Stellbrink, M. Das, E. Daar, 2018, HIV medicine.

Acute myocardial infarction in human immunodeficiency virus-infected patients.

S. Kaul, P. Shah, S. Matetzky, 2003, Archives of internal medicine.

Rapid generation of sequence variation during primary HIV‐1 infection

D. Ho, E. Daar, T. Moudgil, 1992, AIDS.

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

P. Sax, E. Daar, D. Kitch, 2012, AIDS.

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

P. Sax, E. Daar, D. Kitch, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz : ACTG Study A 5224 s

P. Sax, E. Daar, D. Kitch, 2011 .

Impact of randomized antiretroviral therapy initiation on glucose metabolism

P. Sax, E. Daar, D. Kitch, 2014, AIDS (London).

P. Sax, E. Daar, D. Kitch, 2011, The Journal of infectious diseases.

Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection

S. Little, E. Daar, S. Gianella, 2016, AIDS.

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

K. White, P. Sax, J. Gallant, 2022, AIDS.

Lack of Effect of Recombinant Human Growth Hormone on the In Vitro Activities of Antiretroviral Drugs against Human Immunodeficiency Virus Type 1

M. Wainberg, B. Brenner, E. Daar, 2004, Antimicrobial Agents and Chemotherapy.

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

C. Mcevoy, A. Falsey, S. Little, 2021, The New England journal of medicine.

Growth Hormone Improves Lean Body Mass, Physical Performance, and Quality of Life in Subjects With HIV-Associated Weight Loss or Wasting on Highly Active Antiretroviral Therapy

E. Daar, J. Melchior, D. Kotler, 2004, Journal of acquired immune deficiency syndromes.

HIV-1 pol replication capacity predicts disease progression

T. Wrin, E. Daar, S. Donfield, 2005, AIDS.

Novel Viral Markers Predict HIV Disease Progression

E. Daar, 2004 .

Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease.

E. Daar, G. Ehresmann, A. Douvas, 1996, AIDS research and human retroviruses.

The Epidemiology of Invasive Pulmonary Aspergillosis at a Large Teaching Hospital

E. Daar, A. R. Murthy, C. Pegues, 2001, Infection Control & Hospital Epidemiology.

Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease.

E. Daar, S. Donfield, A. Lail, 2005, The Journal of infectious diseases.

Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy

E. Daar, 2009, F1000 medicine reports.

Human Immunodeficiency Virus Inhibits Multilineage Hematopoiesis In Vivo

G. Aldrovandi, E. Daar, J. Zack, 1998, Journal of Virology.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density

P. Sax, E. Daar, D. Kitch, 2013, AIDS.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Real‐Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co‐Encapsulated Ingestion Sensor in HIV‐Infected Patients: A Pilot Study

E. Daar, C. Fletcher, M. Rosen, 2019, Clinical and translational science.

Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It?

E. Daar, Katya Corado, 2016, JAMA.

Primary Human Immunodeﬁciency Virus Type 1 (HIV-1) Infection during HIV-1 Gag Vaccination (cid:1)

O. Yang, Ayub Ali, J. Shiver, 2008 .

HIV transmission in the adult film industry--Los Angeles, California, 2004.

J. Brooks, P. Kerndt, E. Daar, 2005, MMWR. Morbidity and mortality weekly report.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.

T. Holtz, C. del Rio, E. Daar, 2021, The New England journal of medicine.

Clinical and Sociobehavioral Prediction Model of 30-Day Hospital Readmissions Among People With HIV and Substance Use Disorder: Beyond Electronic Health Record Data

E. Halm, Song Zhang, C. del Rio, 2019, Journal of acquired immune deficiency syndromes.

The north-south divide: Substance use risk, care engagement, and viral suppression among hospitalized HIV-infected patients in 11 U.S. cities

L. Metsch, D. Feaster, L. Gooden, 2015 .

Sequential determination of viral load and phenotype in human immunodeficiency virus type 1 infection.

T. Chernyavskiy, E. Daar, J. Zack, 1995, AIDS research and human retroviruses.

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

P. Sax, D. Haas, E. Daar, 2013, The Journal of infectious diseases.

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

R. Haubrich, C. Kemper, E. Daar, 2016, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

HIV Clinical Trials: Important Concepts and Questions

M. Hughes, D. Kuritzkes, P. Sax, 2005 .

Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment

E. Daar, M. Glesby, J. Andersen, 2013, AIDS.

Alterations of gray and white matter volumes and cortical thickness in treated HIV-positive patients.

E. Daar, P. Macey, E. Haroon, 2022, Magnetic resonance imaging.

Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.

G. Bloomfield, K. Tashima, G. Robbins, 2020, The Journal of infectious diseases.

Human immunodeficiency virus type 1 clade B superinfection

D. Richman, S. Little, C. Petropoulos, 2018 .

Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure

P. Hartigan, E. Daar, J. Hamilton, 1997, Annals of Internal Medicine.

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

M. Hughes, E. Daar, Davey M. Smith, 2022, Cell reports. Medicine.

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

M. Hughes, E. Daar, Davey M. Smith, 2021, medRxiv.

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

A. Perelson, S. Pedersen, R. Ribeiro, 2022, Nature Microbiology.

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Karen L. Price, A. Perelson, R. Ribeiro, 2022, Nature Communications.

Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19

A. Perelson, M. Hughes, W. Fischer, 2021, medRxiv.

Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART

C. Spina, E. Daar, S. Gianella, 2016, Journal of acquired immune deficiency syndromes.

Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV

R. Haubrich, E. Daar, D. Moore, 2019, Journal of acquired immune deficiency syndromes.

HIV/AIDS

E. Daar, P. Katsufrakis, 1997, Primary Care: Clinics in Office Practice.

Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men.

R. Haubrich, D. Richman, S. Little, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19

E. Daar, C. Moser, J. Currier, 2022, Open forum infectious diseases.

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

J. Gallant, E. Daar, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

A publication of the International AIDS Society–USA Perspectives HIV Disease Progression: Immune Activation, Microbes, 114 and a Leaky Gut

J. Palefsky, D. Douek, E. Daar, 2007 .

Changes in Proteinuria and Albuminuria With Initiation of Antiretroviral Therapy: Data From a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine Versus Abacavir/Lamivudine

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses

A. Sette, E. Daar, S. Crotty, 2022, JCI insight.

Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs.

S. O’Brien, C. Winkler, E. Daar, 2001, The Journal of infectious diseases.

Modeling plasma virus concentration during primary HIV infection.

A S Perelson, A. Perelson, D. Ho, 2000, Journal of theoretical biology.

Viral and Symptom Rebound in Untreated COVID-19 Infection

E. Daar, Davey M. Smith, C. Moser, 2022, medRxiv.

Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

D. Ho, E. Daar, D D Ho, 1991, The New England journal of medicine.

Utility of fungal blood cultures for patients with AIDS.

E. Daar, T. Mess, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor

R. Doms, W. O'brien, E. Daar, 1997, The Journal of experimental medicine.

Editorial response: Prophylaxis for Pneumocystis carinii pneumonia--an evolving tale of two populations.

E. Daar, P. Gaut, Paula Gaut, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

D. Ho, E. Daar, T. Moudgil, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Faculty Opinions recommendation of HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

E. Daar, 2011 .

Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials

J. Baeten, D. Boulware, K. H. Hullsiek, 2023, Clinical and translational science.

NEUROPATHIC PAIN SECTION Original Research Articles Experience and Challenges Presented by a Multicenter Crossover Study of Combination Analgesic Therapy for the Treatment of Painful HIV-Associated Polyneuropathies

R. Dworkin, D. Clifford, D. Simpson, 2016 .

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients

Todd M. Allen, D. Heckerman, N. Lennon, 2008, Hepatology.

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

C. Fichtenbaum, P. Sax, E. Daar, 2013, The Journal of infectious diseases.

Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients

R. Haubrich, D. Richman, C. Kemper, 2010, AIDS.

Next generation fixed dose combination pharmacotherapies for treating HIV

E. Daar, Katya Corado, Margaret R Caplan, 2018, Expert opinion on pharmacotherapy.

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.

Simon D W Frost, D. Richman, S. Little, 2003, The Journal of infectious diseases.

A Randomized Controlled Trial of Therapeutic Drug Monitoring in Treatment-Naive and -Experienced HIV-1-Infected Patients

R. Haubrich, C. Kemper, J. McCutchan, 2007, Journal of acquired immune deficiency syndromes.

Relation Between HIV‐1 and Hepatitis C Viral Load in Patients With Hemophilia

C. Winkler, E. Daar, D. Chernoff, 2001, Journal of acquired immune deficiency syndromes.

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

R. Lewis, E. Daar, B. Spellberg, 2015, Journal of comparative effectiveness research.

Emerging resistance profiles of newly approved antiretroviral drugs.

E. Daar, 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

P. Sax, E. Daar, K. Robertson, 2014, Annals of Internal Medicine.

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine

M. Lederman, D. Kuritzkes, J. Mellors, 2013, PloS one.

The Effect of Plasma Human Immunodeficiency Virus RNA and CD4+ T Lymphocytes on Growth Measurements of Hemophilic Boys and Adolescents

E. Daar, D. Chernoff, M. Hilgartner, 2001, Pediatrics.

Hepatitis C inflection in dialysis patients: a link to poor clinical outcome?

K. Kalantar-Zadeh, E. Daar, L. Miller, 2006, International Urology and Nephrology.

Clinical targeting of HIV capsid protein with a long-acting small molecule

J. R. Somoza, W. Sundquist, Xiaohong Liu, 2020, Nature.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

D. Podzamczer, K. White, J. Gallant, 2017, The Lancet.

Cytomegalovirus Replication in Semen Is Associated with Higher Levels of Proviral HIV DNA and CD4+ T Cell Activation during Antiretroviral Treatment

R. Haubrich, D. Richman, S. Little, 2014, Journal of Virology.

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

D. Katzenstein, P. Sax, E. Daar, 2011, Annals of Internal Medicine.

Antiretroviral therapy: treatment-experienced individuals.

E. Daar, Katya R Calvo, 2014, Infectious disease clinics of North America.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants

G. Wilding, P. Sax, E. Daar, 2017, Therapeutic drug monitoring.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Lynne Peeples, David Katzenstein, Victoria A Johnson, 2009, The New England journal of medicine.

Factors associated with high transmission risk and detectable plasma HIV RNA in HIV-infected MSM on ART

R. Haubrich, E. Daar, Xiaoying Sun, 2014, International journal of STD & AIDS.

Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy

E. Daar, Katya Corado, Margaret R Caplan, 2018, Drug design, development and therapy.

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202

M. Ritchie, D. Haas, P. McLaren, 2014, Pharmacogenetics and genomics.

Transmission Behaviors of Recently HIV-Infected Men Who Have Sex With Men

S. Little, E. Daar, P. Gorbach, 2006, Journal of acquired immune deficiency syndromes.

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

Marylyn D Ritchie, Gene D Morse, Benjamin J. Grady, 2012, Pharmacogenetics and genomics.

Cerebral Metabolite Abnormalities in Human Immunodeficiency Virus Are Associated with Cortical and Subcortical Volumes

Michael J. Taylor, Jeffery R. Alger, P. Thompson, 2022 .

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols

Marylyn D. Ritchie, Shefali S. Verma, Anurag Verma, 2014, Open forum infectious diseases.

Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART

Michael J. Taylor, Jeffery R. Alger, C. Yiannoutsos, 2014, Journal of NeuroVirology.

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection

E. Daar, C. Moser, J. Currier, 2023, Annals of Internal Medicine.

Limited Nucleotide Changes in the Rev Response Element (RRE) during HIV-1 Infection Alter Overall Rev-RRE Activity and Rev Multimerization

J. Margolick, K. Anastos, E. Daar, 2013, Journal of Virology.

Ineffectual Targeting of HIV-1 Nef by Cytotoxic T Lymphocytes in Acute Infection Results in No Functional Impairment or Viremia Reduction

O. Yang, E. Daar, T. Vollbrecht, 2014, Journal of Virology.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols

R. Haubrich, P. D. de Bakker, G. Robbins, 2015, Pharmacogenetics and genomics.

Increased CD4+ T‐Lymphocyte Senescence Fraction in Advanced Human Immunodeficiency Virus Type 1 Infection

C. Farthing, E. Daar, S. Schneider, 1999, Scandinavian journal of immunology.

Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578)

R. Haubrich, D. Kanouse, C. Kemper, 2006, AIDS.

A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV

E. Daar, M. Rosen, Karen Ablondi, 2015, AIDS and Behavior.

Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection.

R. Schooley, D. Ho, Y. Cao, 1993, The New England journal of medicine.

CD8+ Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection.

O. Yang, E. Daar, A. Balamurugan, 2018, Viral immunology.

Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia

E. Rosenberg, H. Jessen, F. Pereyra, 2014, Journal of Virology.

Early Control of HIV-1 Viremia Impaired Nef Function Is Associated with

E. Rosenberg, H. Jessen, F. Pereyra, 2014 .

Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers

E. Rosenberg, H. Jessen, F. Pereyra, 2010, Journal of Virology.

Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing.

R. Sun, O. Yang, E. Daar, 2014, AIDS research and human retroviruses.

Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells

E. Daar, G. Landucci, D. Forthal, 2001, Journal of Virology.

Relation between HIV-1 and hepatitis C viral load in patients with hemophilia.

C. Winkler, E. Daar, D. Chernoff, 2001 .

Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study.

S. O’Brien, C. Winkler, E. Daar, 1999, Journal of acquired immune deficiency syndromes.

Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection

R. Detels, A. Kaplan, E. Daar, 1996, Journal of virology.

Human Immunodeficiency Virus Type 1 (HIV-1) Diversity at Time of Infection Is Not Restricted to Certain Risk Groups or Specific HIV-1 Subtypes

S. Buchbinder, E. Daar, J. Overbaugh, 2004, Journal of Virology.

Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity.

Susan Little, Douglas Richman, D. Richman, 2009, Virology.

Role of GB Virus C in Human Immunodeficiency Virus Type-1- and Hepatitis C Virus-infected Hemophiliac Children and Adolescents

E. Daar, H. Tillmann, S. Donfield, 2012 .

Role of GB Virus C in HIV-1–Infected and Hepatitis C Virus–Infected Hemophiliac Children and Adolescents

E. Daar, H. Tillmann, S. Donfield, 2012, Journal of acquired immune deficiency syndromes.

Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia.

O. Yang, E. Daar, B. Jamieson, 2011, AIDS research and human retroviruses.

Novel Criteria for Diagnosing Acute and Early HIV Infection in a Multi-National Study of Early Antiretroviral Therapy Initiation.

B. Chi, J. Ananworanich, K. Ruxrungtham, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Behaviors of Recently HIV-Infected Men Who Have Sex With Men in the Year Postdiagnosis: Effects of Drug Use and Partner Types

Robin A. Jeffries, S. Little, R. Weiss, 2011, Journal of acquired immune deficiency syndromes.

Clinical presentation and diagnosis of primary HIV-1 infection

F. Hecht, E. Daar, C. Pilcher, 2008, Current opinion in HIV and AIDS.

Unprotected Anal Intercourse and Substance Use Before and After HIV Diagnosis Among Recently HIV-Infected Men Who Have Sex With Men

S. Little, E. Daar, S. Strathdee, 2006, Sexually transmitted diseases.

Unprotected Anal Intercourse and Substance Use Among Men Who Have Sex With Men With Recent HIV Infection

S. Little, E. Daar, S. Strathdee, 2006, Journal of acquired immune deficiency syndromes.

Primary human immunodeficiency virus type 1 infection

E. Daar, M. Soogoor, 2005, Current HIV/AIDS reports.

Primary HIV-1 infection: Diagnosis, pathogenesis, and treatment

E. Daar, M. Soogoor, 2005, Current infectious disease reports.

Human Immunodeficiency Virus Type 1 Clade B Superinfection: Evidence for Differential Immune Containment of Distinct Clade B Strains

D. Richman, S. Little, C. Petropoulos, 2005, Journal of Virology.

Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.

D. Richman, S. Little, T. Wrin, 2006, Virology.

HIV-1 virulence, fitness and replication capacity

E. Daar, 2005 .

Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.

M. Lederman, D. Kuritzkes, C. Flexner, 2013, The Journal of infectious diseases.

Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood

E. Daar, E. Capparelli, J. Pinto, 2018, Journal of clinical pharmacology.

Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.

M. Hughes, R. Haubrich, P. Sax, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network.

D. Richman, S. Little, S. Mandel, 2001, Annals of internal medicine.

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Matthew C Strain, Diane V Havlir, D. Richman, 2005, The Journal of infectious diseases.

Abnormalities of measles antibody response in human immunodeficiency virus type 1 (HIV-1) infection.

E. Daar, P. Brunell, V. Israele, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid Sites

D. Richman, S. Little, C. Petropoulos, 2000, Journal of Virology.

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study

E. Daar, K. Workowski, B. Doehle, 2016 .

Efavirenz Pharmacogenetics and Weight Gain following Switch to Integrase Inhibitor-containing Regimens.

M. Ritchie, T. Sterling, D. Haas, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.

M. Altfeld, J. Margolick, R. Schooley, 2011, The Journal of infectious diseases.

Leveraging Multi-Ancestry Polygenic Risk Scores for Body Mass Index to Predict Antiretroviral Therapy-Induced Weight Gain*

M. Ritchie, D. Haas, E. Daar, 2022, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.

Unsuspected primary human immunodeficiency virus type 1 infection in seronegative emergency department patients.

S. J. Clark, T. Quinn, G. Shaw, 1994, The Journal of infectious diseases.

Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120

D. Ho, E. Daar, T. Chang, 1992, Journal of virology.

Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with Men

E. Daar, D. Moore, Xiaoying Sun, 2020, AIDS and Behavior.

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men

E. Daar, D. Moore, Xiaoying Sun, 2018, Emerging infectious diseases.

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men

E. Daar, D. Moore, Xiaoying Sun, 2018, Emerging infectious diseases.

Incidence of HIV superinfection following primary infection.

D. Richman, S. Little, E. Daar, 2004, JAMA.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

D. Katzenstein, P. Sax, R. Bosch, 2012, The Journal of infectious diseases.

Emtricitabine + tenofovir alafenamide for the treatment of HIV

E. Daar, Katya Corado, 2017, Expert opinion on pharmacotherapy.

Platelet count is associated with plasma HIV type 1 RNA and disease progression.

E. Daar, S. Donfield, E. Gomperts, 2007, AIDS research and human retroviruses.

Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4

D. Ho, W. O'brien, E. Daar, 1992, Journal of virology.

Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4.

D. Ho, E. Daar, 1991, The American journal of medicine.

Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

D. Ho, J. Robinson, E. Daar, 1991, Journal of virology.

Human immunodeficiency virus and fertility care: embarking on a path of knowledge and access.

E. Daar, J. Daar, 2006, Fertility and sterility.

Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance.

D. Richman, E. Daar, 2005, AIDS research and human retroviruses.

Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies.

R. Lewis, M. Witt, E. Daar, 2008, AIDS patient care and STDs.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

M. Hudgens, R. Haubrich, P. Sax, 2017, The Journal of infectious diseases.

Progressive brain atrophy in chronically infected and treated HIV+ individuals

Michael J. Taylor, T. Nir, N. Jahanshad, 2019, Journal of NeuroVirology.

Clinical Experience With Atovaquone: A New Drug for Treating Pneumocystis Carinii Pneumonia

L. Epstein, E. Daar, Z. Mohsenifar, 1994, The American journal of the medical sciences.

Recombinant Human Growth Hormone in Patients with HIV-Associated Wasting

A. LaMarca, Jack Wang, M. Schambelan, 1996, Annals of Internal Medicine.

Infections in patients with chronic adult T-cell leukemia/lymphoma: case report and review.

E. Daar, J. Said, P. Zakowski, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The acquired immunodeficiency syndrome (AIDS) dementia complex.

H. Vinters, D. Bredesen, E. Daar, 1989, Annals of internal medicine.

Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

E. Rosenberg, B. Walker, D. Richman, 1999, JAMA.

Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial.

C. del Rio, M. Mugavero, L. Metsch, 2016, JAMA.

Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California.

E. Daar, J. Tejero, A. Wohl, 2011, AIDS patient care and STDs.

Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men

E. Daar, D. Moore, Xiaoying Sun, 2018, The Journal of infectious diseases.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

J. Rockstroh, E. Daar, J. Molina, 2018, The lancet. HIV.

Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Lei Wang, Susan Little, Ann Collier, 2006, The Journal of infectious diseases.

Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men

R. Haubrich, E. Daar, S. Gianella, 2015, PloS one.

Individualized diagnosis interventions can add significant effectiveness in reducing human immunodeficiency virus incidence among men who have sex with men: insights from Southern California.

S. Goodreau, D. Wohlfeiler, S. Little, 2015, Annals of epidemiology.

Antiretroviral Drug Resistance and Risk Behavior Among Recently HIV-Infected Men Who Have Sex With Men

S. Little, E. Daar, C. Woelk, 2008, Journal of acquired immune deficiency syndromes.

Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594

Amy M. Sitapati, R. Haubrich, E. Daar, 2018, AIDS and Behavior.

Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy

P. Sax, E. Daar, D. Samuels, 2019, Journal of acquired immune deficiency syndromes.

Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s

P. Sax, E. Daar, D. Kitch, 2015, Journal of acquired immune deficiency syndromes.

Cystatin C-Based Renal Function Changes After Antiretroviral Initiation: A Substudy of a Randomized Trial

P. Sax, E. Daar, D. Kitch, 2014, Open forum infectious diseases.

Strategies for initiating combination antiretroviral therapy.

E. Daar, Kimberly Smith, M. Tapper, 2005, AIDS patient care and STDs.

Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group.

A. LaMarca, J. Wang, M. Schambelan, 1996, Annals of internal medicine.

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection

E. Daar, C. Moser, J. Currier, 2023, Annals of Internal Medicine.

Longitudinal analysis of CD8 T-cell responses to HIV and hepatitis C virus in a cohort of co-infected haemophiliacs

P. Klenerman, R. Phillips, E. Daar, 2005, AIDS.

Diagnosis of Primary HIV-1 Infection

Susan Little, Pauline Ho, Douglas Richman, 2001, Annals of Internal Medicine.

Characteristics of Recently HIV-Infected Men Who Use the Internet to Find Male Sex Partners and Sexual Practices With Those Partners

S. Little, S. Frost, E. Daar, 2006, Journal of acquired immune deficiency syndromes.

Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection

L. Metsch, D. Feaster, R. Mandler, 2018, AIDS and Behavior.

Molecular analysis of HIV strains from a cluster of worker infections in the adult film industry, Los Angeles 2004

J. Brooks, M. Kalish, P. Kerndt, 2006, AIDS.

Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19

E. Daar, T. Hatlen, Kirk B. Fetters, 2022, Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202

D. Haas, E. Daar, E. Acosta, 2015, Pharmacogenetics and genomics.

Virologic correlates of anti-CMV IgG levels in HIV-1-infected men.

R. Haubrich, D. Richman, S. Little, 2014, The Journal of infectious diseases.

Newer antiretroviral agents and how to use them

E. Daar, Holly H Kim, 2009, Current HIV/AIDS reports.

Newer antiretroviral agents and how to use them

E. Daar, Holly H Kim, 2009, Current infectious disease reports.

Antiretroviral regimens for treatment-experienced patients with HIV-1 infection

E. Daar, M. Lagnese, 2008, Expert opinion on pharmacotherapy.

Effects of Nadir Cd4 Count and Duration of Human Immunodeficiency Virus Infection on Brain Volumes in the Highly Active Antiretroviral Therapy Era

Jianhui Zhong, Michael J. Taylor, Jaroslaw Harezlak, 2022 .

Dual protease inhibitor therapy in the management of the HIV-1

E. Daar, Kalvin C. Yu, 2000, Expert opinion on pharmacotherapy.

Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19

H. Masur, E. Daar, P. Tebas, 2021, Annals of Internal Medicine.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

D. Katzenstein, P. Sax, E. Daar, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genetic Basis of Hypersusceptibility to Protease Inhibitors and Low Replicative Capacity of Human Immunodeficiency Virus Type 1 Strains in Primary Infection

J. Corbeil, J. Margolick, D. Richman, 2004, Journal of Virology.

Viral suppression and HIV transmission behaviors among hospitalized patients living with HIV

C. del Rio, L. Metsch, D. Feaster, 2019, International journal of STD & AIDS.

A community-partnered approach for diversity in COVID-19 vaccine clinical trials

Arleen F. Brown, E. Daar, D'Ann M Morris, 2022, Journal of Clinical and Translational Science.

Primary Human Immunodeficiency Virus Type 1 (HIV-1) Infection during HIV-1 Gag Vaccination

O. Yang, Ayub Ali, J. Shiver, 2008, Journal of Virology.

Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men

R. Haubrich, E. Daar, Xiaoying Sun, 2016, AIDS and Behavior.

Novel approaches to HIV therapy

E. Daar, 2017, F1000Research.

Infectious decay of human immunodeficiency virus type 1 in plasma.

E. Daar, T. Moudgil, 1993, The Journal of infectious diseases.

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy

R. Ribeiro, E. Daar, D. Smith, 2021, medRxiv.

Hepatitis C virus infection and neurocognitive function

E. Daar, S. Donfield, E. Gomperts, 2006, Neurology.

Generalizing evidence from randomized trials using inverse probability of sampling weights

Michael G Hudgens, Stephen R Cole, Michael J Mugavero, 2018, Journal of the Royal Statistical Society. Series A,.

Patterns of CNS Injury in HIV Infection : a DTI Tract-Based Spatial Statistics Study

C. Yiannoutsos, S. Ekholm, R. Cohen, 2010 .

Initiation of Antiretroviral Therapy in the Hospital is Associated with Linkage to HIV Care for Persons Living with HIV and Substance Use.

C. del Rio, L. Metsch, D. Feaster, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Potency and Durability of Antiretroviral Therapy

E. Daar, 2003, Journal of acquired immune deficiency syndromes.

Primary HIV-1 infection.

S. J. Clark, D. Ho, J. Levy, 1991, The New England journal of medicine.

treated HIV-1 infected men who have sex with men

R. Haubrich, S. Little, C. Ginocchio, 2013 .

Two-drug regimens for HIV treatment.

P. Sax, P. Cahn, E. Daar, 2022, The lancet. HIV.

Pharmacokinetics of Co-encapsulated Antiretrovirals with Ingestible Sensors.

E. Daar, C. Fletcher, M. Rosen, 2020, AIDS research and human retroviruses.

Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy

C. Ginocchio, E. Daar, S. Gianella, 2015, BMC Infectious Diseases.

semen is associated with higher levels of proviral HIV DNA and CD 4 + T cell activation during antiretroviral treatment

R. Haubrich, D. Richman, S. Little, 2014 .

Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy

Michael J. Taylor, C. Yiannoutsos, R. Heaton, 2013, Journal of NeuroVirology.

Open-label, randomized, parallel-group controlled clinical trial of massage for treatment of depression in HIV-infected subjects.

R. Poland, E. Daar, U. Rao, 2013, Journal of alternative and complementary medicine.

The North-South Divide: Substance Use Risk, Care Engagement, and Viral Suppression Among Hospitalized Human Immunodeficiency Virus–Infected Patients in 11 US Cities

C. del Rio, L. Metsch, D. Feaster, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Virology and immunology of acute HIV type 1 infection.

E. Daar, 1998, AIDS research and human retroviruses.

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study

R. Parker, K. Freedberg, D. Rabideau, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Epidemiologic investigation of a cluster of workplace HIV infections in the adult film industry: Los Angeles, California, 2004.

Bruce P. Bernard, Lisa V. Smith, J. Brooks, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance

Susanne May, Christopher H Woelk, J. Margolick, 2008, AIDS.

Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-Infected Subjects ACTG 5200

D. Weiner, E. Daar, D. Reeds, 2010, Journal of acquired immune deficiency syndromes.

Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: An open-label, usual care-controlled, randomised trial

E. Daar, G. Savage, C. Fletcher, 2022, EBioMedicine.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Tania B. Huedo-Medina, M. Hughes, P. Sax, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Acute HIV Syndrome after Discontinuation of Antiretroviral Therapy in a Patient Treated before Seroconversion

E. Daar, J. Giorgi, J. Bai, 1998, Annals of Internal Medicine.

Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19

E. Daar, C. Fletcher, C. Moser, 2023, JAMA network open.

Cost-Effectiveness Analysis of Ugt1A1 Genetic Testing to Inform Antiretroviral Prescribing in HIV Disease

K. Freedberg, P. Sax, D. Haas, 2013, Antiviral therapy.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

P. Sax, E. Daar, A. Collier, 2019, Antimicrobial Agents and Chemotherapy.

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

E. Daar, C. Fletcher, C. Moser, 2023, Annals of Internal Medicine.

Primary human immunodeficiency virus type 1 infection in pregnancy.

E. Daar, A. Keerasuntonpong, P. Gaut, 1999, Obstetrics and gynecology.

Diagnosing Primary HIV Infection

S. Little, E. Daar, 2002 .

Primary HIV infection

E. Daar, Kalvin C. Yu, 2000, Postgraduate medicine.

Herpes simplex virus type 2 seroprevalence and incidence in acute and chronic HIV-1 infection

E. Daar, P. Christenson, G. Rieg, 2011, International Journal of STD and AIDS.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols

R. Haubrich, P. D. de Bakker, G. Robbins, 2015, Pharmacogenetics and genomics.

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody

A. Perelson, R. Ribeiro, E. Daar, 2023, bioRxiv.

Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy

Michael J. Taylor, C. Yiannoutsos, J. Alger, 2015, Journal of acquired immune deficiency syndromes.

Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment

E. Daar, M. Glesby, J. Andersen, 2013, AIDS.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients

Todd M. Allen, D. Heckerman, N. Lennon, 2008, Hepatology.

Generalizing evidence from randomized trials using inverse probability of sampling weights

Ashley L. Buchanan, S. Cole, M. Hudgens, 2018, Journal of the Royal Statistical Society. Series A,.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Seminal plasma HIV levels in men with asymptomatic sexually transmitted infections

E. Daar, D. Smith, G. Rieg, 2010, International journal of STD & AIDS.

Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era

Michael J. Taylor, Jeffery R. Alger, P. Thompson, 2010, Journal of NeuroVirology.

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

M. Hughes, E. Daar, Davey M. Smith, 2022, Cell Reports Medicine.

Immune Status and SARS-CoV-2 Viral Dynamics.

E. Daar, C. Moser, J. Currier, 2023, The Journal of infectious diseases.

Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202

D. Katzenstein, P. Sax, A. Zolopa, 2013, HIV clinical trials.

Variant-Specific Viral Kinetics in Acute COVID-19.

A. Perelson, R. Ribeiro, E. Daar, 2023, The Journal of infectious diseases.

Impact of randomized antiretroviral therapy initiation on glucose metabolism

P. Sax, E. Daar, D. Kitch, 2014, AIDS.

Antiretroviral Drug Resistance and Risk Behavior Among Recently HIV-Infected Men Who Have Sex With Men

S. Little, E. Daar, C. Woelk, 2008, Journal of acquired immune deficiency syndromes.

Human Immunodeficiency Virus Type 1 Clade B Superinfection: Evidence for Differential Immune Containment of Distinct Clade B Strains

D. Richman, S. Little, C. Petropoulos, 2005, Journal of Virology.

Implementation and Operational Research: The Navigation Program An Intervention to Reengage Lost Patients at 7 HIV Clinics in Los Angeles County, 2012–2014

E. Daar, J. Bailey, A. Wohl, 2016, Journal of acquired immune deficiency syndromes.